AstraZeneca announced the first patient randomized in the Phase 3 clinical program for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive.
The SELumetinib Evaluation as Combination Therapy-1 (SELECT-1) study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of selumetinib plus docetaxel as a second line therapy in locally advanced or metastatic KRAS mutation-positive NSCLC. The study is designed to evaluate Progression Free Survival (PFS) and Overall Survival (OS). SELECT-1 will be the largest prospective study ever conducted in this patient population, a genetic sub-type of lung cancer associated with poor prognosis and limited treatment options.
The decision to progress selumetinib to Phase 3 studies in NSCLC followed the results from Study 16, a randomized Phase 2 study evaluating the combination of selumetinib with standard of care docetaxel against docetaxel alone in KRAS-mutation positive NSCLC. Study 16 demonstrated a high and durable response rate of 37.2 percent versus 0 percent, translating into a statistically significant improvement in progression free survival (PFS) of 5.3 versus 2.1 months.
AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma in 2003.
Antoine Yver, vice president and head of Oncology in AstraZeneca’s Global Medicines Development unit said: “To our knowledge, SELECT-1 will be the first Phase 3 study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone in KRAS mutation positive advanced or metastatic non-small cell lung cancer. This is an area of pressing clinical need, and our decision to progress selumetinib was based on Phase 2 results, which showed promising clinical activity in this group of patients.”
Date: October 22, 2013
Source: AstraZeneca
Filed Under: Drug Discovery
